Home
ACRV
ACRV News

Latest Acrivon Therapeutics Inc. (ACRV) News on July 31, 2025

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

TipRanks

2 months ago

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

MT Newswires

3 months ago

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

3 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now

Zacks

3 months ago

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

GlobeNewswire

3 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

April 2025's Standout Penny Stocks

Simply Wall St.

3 months ago

April 2025's Standout Penny Stocks

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

Zacks

4 months ago

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

MT Newswires

4 months ago

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

GlobeNewswire

4 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Zacks

4 months ago

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks

Zacks

4 months ago

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

4 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

GlobeNewswire

4 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

MT Newswires

4 months ago

Acrivon Therapeutics Names Adam Levy as CFO

We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

Simply Wall St.

6 months ago

We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

Acrivon Therapeutics announces FDA granted BDD for ACR-368

TipRanks

6 months ago

Acrivon Therapeutics announces FDA granted BDD for ACR-368

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay

Medical Device Network

6 months ago

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay

MT Newswires

6 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

Insider Monkey

6 months ago

Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status

MT Newswires

6 months ago

Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

GlobeNewswire

6 months ago

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

MT Newswires

6 months ago

Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

9 months ago

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

GlobeNewswire

9 months ago

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

TipRanks

10 months ago

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

MT Newswires

10 months ago

Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

GlobeNewswire

10 months ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

MT Newswires

10 months ago

Ladenburg Thalmann Upgrades Acrivon Therapeutics to Buy From Neutral

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

GlobeNewswire

a year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

GlobeNewswire

a year ago

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

GlobeNewswire

a year ago

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

Zacks

a year ago

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

5 Small Drug Stocks to Buy From a Recovering Industry

Zacks

a year ago

5 Small Drug Stocks to Buy From a Recovering Industry

Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?

Zacks

a year ago

Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?

Zacks

a year ago

Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?

While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership

Simply Wall St.

a year ago

While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership

MT Newswires

a year ago

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

GlobeNewswire

a year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

GlobeNewswire

a year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

GlobeNewswire

a year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

Acrivon Therapeutics Announces $130 Million Private Placement Financing

GlobeNewswire

a year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

GuruFocus.com

a year ago

Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

GlobeNewswire

a year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

GlobeNewswire

a year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

GlobeNewswire

a year ago

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

a year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

GlobeNewswire

a year ago

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

a year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quest Resource Holding Corporation's (NASDAQ:QRHC) top owners are retail investors with 36% stake, while 21% is held by institutions

Simply Wall St.

2 years ago

Quest Resource Holding Corporation's (NASDAQ:QRHC) top owners are retail investors with 36% stake, while 21% is held by institutions

Canopy Growth to Report Third Quarter Fiscal 2024 Financial Results on February 9, 2024

CNW Group

2 years ago

Canopy Growth to Report Third Quarter Fiscal 2024 Financial Results on February 9, 2024

NextNav Announces Appointment of John Muleta to Board of Directors

GlobeNewswire

2 years ago

NextNav Announces Appointment of John Muleta to Board of Directors

FingerMotion Provides Supplemental Quarterly Guidance

ACCESSWIRE

2 years ago

FingerMotion Provides Supplemental Quarterly Guidance

Zentek Announces Eric Wallman Appointed as Chairman of the Board

ACCESSWIRE

2 years ago

Zentek Announces Eric Wallman Appointed as Chairman of the Board

Franklin Street Properties Corp. Announces Tax Composition of 2023 Distributions

Business Wire

2 years ago

Franklin Street Properties Corp. Announces Tax Composition of 2023 Distributions

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

GlobeNewswire

2 years ago

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Zacks

2 years ago

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Senior Vice President David Knutson Sells 20,000 Shares of NextNav Inc

GuruFocus.com

2 years ago

Senior Vice President David Knutson Sells 20,000 Shares of NextNav Inc

Industrial Logistics Properties Trust Announces Quarterly Dividend on Common Shares

Business Wire

2 years ago

Industrial Logistics Properties Trust Announces Quarterly Dividend on Common Shares

Seanergy Maritime Holdings Corp (SHIP) is a Great Momentum Stock: Should You Buy?

Zacks

2 years ago

Seanergy Maritime Holdings Corp (SHIP) is a Great Momentum Stock: Should You Buy?

Tilly's (TLYS) Posts Soft Holiday Sales, Comps Decline 9%

Zacks

2 years ago

Tilly's (TLYS) Posts Soft Holiday Sales, Comps Decline 9%

RED ROBIN UNLEASHES FAMOUS GOURMET BURGERS, BREWS AND FUN AT NEWEST LOCATION IN ROSSFORD, OHIO

PR Newswire

2 years ago

RED ROBIN UNLEASHES FAMOUS GOURMET BURGERS, BREWS AND FUN AT NEWEST LOCATION IN ROSSFORD, OHIO

Monthly information on share capital and company voting rights

GlobeNewswire

2 years ago

Monthly information on share capital and company voting rights

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Business Wire

2 years ago

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

GlobeNewswire

2 years ago

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

PR Newswire

2 years ago

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

Butterfly Network Announces Commercial Agreement with Mendaera for Next-Generation Interventional Robotic System Powered by Butterfly's Ultrasound-on-Chip™ Technology

Business Wire

2 years ago

Butterfly Network Announces Commercial Agreement with Mendaera for Next-Generation Interventional Robotic System Powered by Butterfly's Ultrasound-on-Chip™ Technology

Nature Wood Group Limited Announces First Half 2023 Unaudited Financial Results

PR Newswire

2 years ago

Nature Wood Group Limited Announces First Half 2023 Unaudited Financial Results

System1 to Participate in the 2024 ICR Conference

Business Wire

2 years ago

System1 to Participate in the 2024 ICR Conference

One G. Willi-Food International Insider Raised Stake By 15% In Previous Year

Simply Wall St.

2 years ago

One G. Willi-Food International Insider Raised Stake By 15% In Previous Year

GlobeNewswire

2 years ago

Gencor Releases Fourth Quarter and Fiscal Year 2023 Results

Will Qurate Retail (QRTEA) Benefit from “Project Athens”?

Insider Monkey

2 years ago

Will Qurate Retail (QRTEA) Benefit from “Project Athens”?

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

GlobeNewswire

2 years ago

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

NextNav Announces CEO Transition

GlobeNewswire

2 years ago

NextNav Announces CEO Transition

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

GlobeNewswire

2 years ago

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

GlobeNewswire

2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Markforged Receives Continued Listing Standards Notice from the NYSE

Business Wire

2 years ago

Markforged Receives Continued Listing Standards Notice from the NYSE

Geospace Technologies Corporation's (NASDAQ:GEOS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Simply Wall St.

2 years ago

Geospace Technologies Corporation's (NASDAQ:GEOS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

TH International Limited (NASDAQ:THCH) Screens Well But There Might Be A Catch

Simply Wall St.

2 years ago

TH International Limited (NASDAQ:THCH) Screens Well But There Might Be A Catch

Gabelli Global Small and Mid Cap Value Trust Declares Fourth Quarter Distribution of $0.16 Per Share

GlobeNewswire

2 years ago

Gabelli Global Small and Mid Cap Value Trust Declares Fourth Quarter Distribution of $0.16 Per Share

Gabelli Funds and Columbia Business School to Host 5th Annual Healthcare Symposium

GlobeNewswire

2 years ago

Gabelli Funds and Columbia Business School to Host 5th Annual Healthcare Symposium

Share on Social Networks: